Form 4: KALA BIO Director Andrew Koven Reports Acquisition of Stock Options and Restricted Stock Units
SEC Form 4 Filing
Director Andrew Koven reported the acquisition of stock options and restricted stock units in KALA BIO, Inc.
Summary
- On June 11, 2024, Andrew I Koven, a director of KALA BIO, Inc., reported the acquisition of 1,750 shares of common stock in the form of restricted stock units (RSUs) and stock options for 3,900 shares.
- The RSUs were granted under the company's Amended and Restated 2017 Equity Incentive Plan.
- The RSUs will vest as to 100% of the shares on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024, subject to continued service.
- The stock options, with an exercise price of $6.18, also vest as to 100% of the shares on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024.
- Following these transactions, Koven beneficially owns 13,922 shares of common stock, including 10,864 unvested RSUs, and stock options for 3,900 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the company's future, but it's a routine transaction.
Positives
- The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule, contingent on continued service, incentivizes the director to remain with the company.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting of RSUs and stock options is tied to continued service, suggesting an expectation of ongoing involvement from the director.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry to incentivize and retain key personnel.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with theirs.
- Employees may see this as a positive indicator of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Grant of restricted stock units and stock options. |
| 06/11/2025 | Vesting date for RSUs and stock options (or earlier if the first annual meeting following June 11, 2024 occurs before this date). |
| 06/10/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.